Lead Sponsor

Janssen Research & Development, LLC

Age

18 - 80 years

Sex

ALL

Healthy Volunteers

Yes

•Must have stable renal function defined as a less than (\<) 20 percent (%) change in serum creatinine concentrations between screening and Day -1
•Concomitant medications should be stable for the previous 1 month and throughout the duration of the study
•Women, except for postmenopausal women, must have a negative highly sensitive serum (beta-human chorionic gonadotropin \[beta-hCG\]) at screening and urine (beta-hCG) pregnancy test on Day -1
•Must sign an informed consent form (ICF) indicating they understand the purpose of, and procedures required for the study and are willing to participate in the study
•Participants with kidney disease without dialysis using benzodiazepines, tricyclic antidepressants, and prescription opiates with a positive urine test for drugs prescribed by their physician may be included following prior discussion with the sponsor

•Have kidney disease requiring dialysis
•Renal transplants, systemic lupus erythematosus, or participant with malignancy
•Known allergies, hypersensitivity, or intolerance to JNJ-73763989 or its excipients
•Received an experimental drug (including investigational vaccines) or used an experimental medical device within 1 month or within a period less than 10 times the drug's half-life, whichever is longer, before the administration of the study drug is scheduled
•Preplanned surgery or procedures that would interfere with the conduct of the study

Related studies

NCT07154901 · Renal Impairment

NCT07165015 · Renal Impairment, Healthy, and more

NCT07551570 · Renal Impairment

NCT06693765 · Renal Impairment, End-stage Kidney Disease, and more

NCT06352411 · Healthy, Renal Impairment

A Study of JNJ-73763989 in Adult Participants With Renal Impairment